PAEDIATRIC
PAEDIATRIC
CENTRAL NERVOUS INFECTIONS
In this topic:
1.1 Meningitis Empirical Treatment
Age groups:
< 1 month:
Group B streptococcus (GBS)
E. coli
1-3 months:
Group B streptococcus (GBS)
E. coli
S. pneumoniae
N. meningitidis
> 3 months:
S. pneumoniae,
Hib
E. coli
Salmonellosis
N. meningitidis
Preferred
Cefotaxime 200-300mg/kg/day IV in 4 divided doses (max. 2g/dose)
OR
Ceftriaxone 100mg/kg/day IV in 2 divided doses
(max. 2g/dose; 4g/day)
Alternative
--
Comments
For children below 3 months of age:
Cefotaxime is the preferred third generation cephalosporin since less drug-drug interactions (in terms of interaction with calcium-containing infusion & bilirubin displacement).
Given the commonality of GBS in this age group, adding IV C Penicillin (Benzylpenicillin) to Cefotaxime while awaiting culture results can be considered.
Once organism is known, please refer below to adjust antibiotics and duration.
1.2 Specific Organisms
1.2.1 Group B streptococcus (GBS)
Preferred
Benzylpenicillin 300,000-400,000 units/kg/day IV in 4-6 divided doses (max. 24 million units/day)
Alternative
--
Comments
Duration: 14 days
1.2.2 Haemophilus influenza (HI)
Preferred
Cefotaxime 200-300mg/kg/day IV in 4 divided doses (max. 2g/dose)
OR
Ceftriaxone 100mg/kg/day IV in 1 or 2 divided doses (max. 2g/dose; 4g/day)
Alternative
Ampicillin 300mg/kg/day q6h (max. 12g/day)
(if MIC <1mcg/mL)
Comments
Duration: 10 days
1.2.3 Neisseria meningitidis
Preferred
Benzylpenicillin 300,000-400,000 units/kg/day; max. 12 million units/day) IV in 4-6 divided doses
OR
Ceftriaxone 100mg/kg/day IV in 2 divided doses (max. 2g/dose; 4g/day)
Alternative
--
Comments
Duration: 7 days
Prophylaxis for all household contacts & health care workers involved in unprotected contact during intubation & suctioning of airway/mouth-to-mouth resuscitation.
1.2.4 Streptococcus pneumonia (SP)
Preferred
Benzylpenicillin 300,000-400,000 units/kg/day in 4-6 divided doses (max. 24 million units/day)
Penicillin-resistant (MIC≥0.12 mcg/ml) & cefotaxime/ ceftriaxone- sensitive (MIC ≤0.5 mcg/mL):
Cefotaxime 200-300mg/kg/day IV in 4 divided doses (max. 2g/dose)
OR
Ceftriaxone 100mg/kg/day IV in 2 divided doses (max. 2g/dose; 4g/day)
*Penicillin & cefotaxime/ceftriaxone-nonsusceptible (MIC ≥1.0 mcg/ml) (drug-resistant Streptococcus pneumoniae, DRSP):
High dose cefotaxime 300mg/kg/day IV in 4 divided doses (max. 12g/day) or ceftriaxone 100mg/kg/day IV in 1 or 2 divided doses (max. 2g/dose; 4g/day)
PLUS
Vancomycin 60mg/kg/day in 3 divided doses (max. 2g/day unless unable to achieve therapeutic level). Target AUC24 of 400-600 mg*hour/L
Alternative
--
Comments
Duration: 14 days
*Treat in consultation with ID specialist.
1.2.5 Cryptococcal Meningitis
Cryptococcus neoformans
Preferred
Induction Therapy:
Amphotericin B 1.0mg/kg/day IV q24h
MAY ADD 5-flucytosine 25mg/kg/dose (max. 2g/dose) PO q6h for 2-4 weeks
Consolidation Therapy:
Fluconazole 6-12mg/kg/dose (max. 400mg/dose) IV/PO q24h for 8 weeks
Alternative
--
Comments
Duration of induction with 5-flucytosine (5-FU) is at least 2 weeks & until CSF repeat culture is NEGATIVE.
2.1 Herpes simplex Encephalitis
Preferred
Pediatric herpes CNS disease:
> 4month to 12 years old
Acyclovir 30-45mg/kg/day IV in 3 divided doses
> 12 years old
Acyclovir 30mg/kg/day IV in 3 divided doses
Neonatal herpes CNS disease:
IV Acyclovir 60mg/kg/day in 3 divided doses
Alternative
--
Comments
Duration: 21 days minimum.
Dosing exceeding 500mg/m2 can be associated with acute kidney injury.
Preferred
Cefotaxime 200-300mg/kg/day IV in 4 divided doses (max. 2g/dose)
OR
Ceftriaxone 100mg/kg/day IV in 2 divided doses (max. 2g/dose; 4g/day)
PLUS
Metronidazole 15mg/kg IV stat then 7.5mg/kg IV q8h (max. 4g/day)
Alternative
If secondary to trauma:
PLUS
Cloxacillin 200-300mg/kg/day in 4-6 divided doses (max. 12g/day)
(Add to third generation cephalosporin)
Comments
Surgical drainage may be indicated if appropriate.
Duration: 6-8 weeks, depending on response based on neuroimaging & clinical presentations.
References:
American Academy of Paediatrics. Committee on Infectious Diseases. Red Book: Report of the Committee on Infectious Diseases (2021)
Sanford Guide to Antimicrobial Therapy 2022